PT  - JOURNAL ARTICLE
AU  - Kakati, Kaberi
AU  - Rahman, Tashnin
AU  - Barman, Debabrata
AU  - Bhattacharyya, Mouchumee
AU  - Borthakur, Bibhuti Bhusan
AU  - Barman, Rashmisnata
AU  - Kalita, Apurba
AU  - Kataki, Amal Chandra
AU  - Krishnatreya, Manigreeva
TI  - Mortality audit of cancer patients with SARS-CoV-2 positivity or COVID-19
AID  - 10.1101/2021.05.21.21257574
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.21.21257574
4099  - http://medrxiv.org/content/early/2021/05/28/2021.05.21.21257574.short
4100  - http://medrxiv.org/content/early/2021/05/28/2021.05.21.21257574.full
AB  - Coronavirus disease-2019 (COVID-19) has disrupted cancer care services globally. The present review of cause of deaths was conducted in a tertiary care cancer center in the North East India. In our institute, all cancer patients requiring admission for surgery, chemotherapy, and other daycare procedures require testing for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). From 09 July 2020 to 16 May 2021, 119 cancer patients with SARS-CoV-2 positive report or COVID-19 have been admitted at our institute Covid ward. A total of 19 cancer patients with COVID-19 succumbed. Of 19 deaths, 13 (68.4%) patients were men and 6 (31.6%) patients were women. The age range from 27 years to 74 years (median =55 years). Vomiting alone or with diarrhea was the most common symptom requiring admission after testing (4/19, 21.0%), followed by bleeding from primary tumour site (3/19, 15.7%). The antecedent and underlying cause of deaths in 19 (100%) patients was cancer. SARS-CoV-2 infection should not be a hindrance for cancer treatment and management.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Ethics Committee of Dr B Borooah Cancer InstituteAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesYes. In excel spreadsheet. Can be provided upon request